Therapeutic drug monitoring of levetiracetam by high-performance liquid chromatography with photodiode array ultraviolet detection: Preliminary observations on correlation between plasma concentration and clinical response in patients with refractory epilepsy

Therapeutic Drug Monitoring

Volumn 29, Issue 5, 2007, Pages 576-583

  Lancelin, Frédérique ^a   Franchon, Emilie ^a   Kraoul, Linda ^a   Garciau, Isabelle ^a   Brovedani, Sophie ^a   Tabaouti, Khalid ^a   Landré, Elisabeth ^a   Chassoux, Francine ^a   Paubel, Pascal ^a   Piketty, Marie Liesse ^a  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

Epilepsy; Levetiracetam; Therapeutic drug monitoring

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID;

ADOLESCENT; ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG INTOXICATION; DRUG MONITORING; EPILEPSY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; ULTRAVIOLET RADIATION;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; DRUG RESISTANCE; EPILEPSY; FEMALE; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; PIRACETAM; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 34848887217     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318157032d     Document Type: Article

References (25)

1. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43:707-724.
2. Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia 2001;42(Suppl 4):24-27.
3. Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit. 2003;25:347-363.
4. Perruca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet. 2000;38:191-204.
5. Commission on antiepileptic drugs, international league against epilepsy. Guidelines for therapeutic monitoring on antiepileptic drugs. Epilepsia. 1993;34:585-587.
6. Perry PJ, Miller DD, Arndt SV, et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry. 1991;148:231-235.
7. Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol. 1994;14:230-240.
8. Leppik IE. Compliance during treatment of epilepsy. Epilepsia. 1988;29(Suppl 2):S79-S84.
9. Vermeij TAC, Edelbroek PM. High-performance liquid chromatographic and megabore gas-liquid chromatographic determination of levetiracetam (UCB L059) in human serum after solid-phase extraction. J Chromatogr B. 1994;662:134-139.
10. Martens-Lobenhoffer J, Bode-Böger SM. Determination of levetiracetam in human plasma with minimal sample pretreatment. J Chromatgr B. 2005;819:197-200.
11. Ratnaraj N, Doheny HC, Patsalos PN. A micromethod for the determination of the new antiepileptic drug levetiracetam (UCB L059) in serum or plasma by high performance liquid chromatography. Ther Drug Monit. 1996;18:154-157.
12. Pucci V, Bugamelli F, Mandrioli R, et al. High-performance liquid chromatographic determination of levetiracetam in human plasma: comparison of different sample clean-up procedures. Biomed Chromatogr. 2004;18:37-44.
13. Juenke JM, Brown PI, Urry FM, et al. Drug monitoring and toxicology: a procedure for the monitoring of levetiracetam and zonisamide by HPLCUV. J Anal Toxicol. 2006;30:27-30.
14. May TW, Rambeck B, Jürgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit. 2003;25:690-699.
15. Patsalos PN. The pharmacokinetic characteristics of levetiracetam. Methods Find Exp Clin Pharmacol. 2003;25:123-129.
16. Contin M, Albani F, Riva R, et al. Levetiracetam therapeutic monitoring in patients with epilepsia: effect of concomitant antiepileptic drugs. Ther Drug Monit. 2004;26:375-379.
17. Perucca E, Gidal BE, Batlès E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res. 2003;53:47-56.
18. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia. 2000;41:1276-1283.
19. Steinhoff BJ, Trinka E, Wieser HG. Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland. Seizure. 2005;14:490-496.
20. Abou-Khalil B, Schaich L. Long-term efficacy of levetiracetam for partial seizures. Seizure. 2005;14:577-585.
21. Leppik IE, Rarick JO,Walezak TS, et al. Effective levetiracetam doses and serum concentrations: age effects. Epilepsia. 2002;43(Suppl 7):240.
22. Folland C, Moriarty GL. Clinical experience of levetiracetam (LEV) in refractory adult epilepsy patients. Epilepsia. 2002;43(Suppl 7):192.
23. Juenke JM, Brown PI, Urry FM. Analysis of levetiracetam and zonisamide in plasma and serum by HPLC. Clin Chem. 2002;48(Suppl 6):44-45.
24. Barrueto F, Williams K, Howland MA, et al. A case of levetiracetam (Keppra) poisoning with clinical and toxicokinetic data. J Toxicol Clin Toxicol. 2002;40:881-884.
25. Welty TE, Gidal BE, Ficker DM, et al. Levetiracetam: a different approach to the pharmacotherapy of epilepsy. Ann Pharmacother. 2002;36:296-304.